
Orogen Therapeutics Selects Two Development Candidates for Immune Diseases, Targeting IL-17 and JAK1/TYK2
Orogen Therapeutics Selects ORO-110 and ORO-210 Development Candidates for Inflammatory Diseases Orogen Therapeutics, Inc. (“Orogen” or the “Company”) announced the selection of two development candidates, ORO-110 and ORO-210, as potential…














